| Umsatz in Mio. | 1,00 $ |
| Operatives Ergebnis (EBIT) in Mio. | -22,41 $ |
| Jahresüberschuss in Mio. | -19,99 $ |
| Umsatz je Aktie | 0,12 $ |
| Gewinn je Aktie | -2,40 $ |
| Gewinnrendite | -67,58% |
| Umsatzrendite | - |
| Return on Investment | -57,10% |
| Marktkapitalisierung in Mio. | 24,82 $ |
| KGV (Kurs/Gewinn) | -1,24 |
| KBV (Kurs/Buchwert) | 0,84 |
| KUV (Kurs/Umsatz) | 24,83 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +84,48% |
| Geld/Brief | 2,01 $ / 2,44 $ |
| Spread | +21,39% |
| Schluss Vortag | 2,06 $ |
| Gehandelte Stücke | 3.410 |
| Tagesvolumen Vortag | 16.340,2 $ |
| Tagestief 2,01 $ Tageshoch 2,01 $ | |
| 52W-Tief 1,81 $ 52W-Hoch 4,20 $ | |
| Jahrestief 1,81 $ Jahreshoch 4,20 $ | |
| 31.12.2025 | Quartalsmitteilung |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 1,70 € | -2,30% | 1,74 € | 16:32 | |
| Frankfurt | 1,67 € | +1,83% | 1,64 € | 08:03 | |
| München | 1,72 € | +1,18% | 1,70 € | 08:00 | |
| Stuttgart | 1,70 € | +2,41% | 1,66 € | 07:36 | |
| L&S RT | 1,745 € | -0,85% | 1,76 € | 17:54 | |
| Berlin | 1,74 € | -2,25% | 1,78 € | 17:12 | |
| NYSE | 2,16 $ | +5,11% | 2,055 $ | 10.12.25 | |
| Nasdaq | 2,01 $ | -2,43% | 2,06 $ | 15:30 | |
| AMEX | 2,03 $ | +0,50% | 2,02 $ | 18.11.25 | |
| Tradegate | 1,86 € | +5,08% | 1,77 € | 09.12.25 | |
| Quotrix | 1,76 € | +2,33% | 1,72 € | 07:27 | |
| Gettex | 1,73 € | -3,35% | 1,79 € | 17:44 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 10.12.25 | 2,06 | 17.201 |
| 09.12.25 | 2,00 | 9.327 |
| 08.12.25 | 1,95 | 12.374 |
| 05.12.25 | 1,97 | 12.365 |
| 04.12.25 | 2,05 | 8.128 |
| 03.12.25 | 1,92 | 9.887 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 1,92 $ | +7,29% |
| 1 Monat | 2,12 $ | -2,83% |
| 6 Monate | 2,58 $ | -20,16% |
| 1 Jahr | 2,78 $ | -25,90% |
| 5 Jahre | 24,75 $ | -91,68% |
| Marktkapitalisierung | 15,38 Mio. € |
| Aktienanzahl | 8,39 Mio. |
| Streubesitz | 71,00% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +2,90% | Vanguard Group Inc |
| +2,40% | BML Capital Management LLC |
| +1,17% | Renaissance Technologies Corp |
| +0,70% | Geode Capital Management, LLC |
| +0,63% | BlackRock Inc |
| +0,29% | Dimensional Fund Advisors, Inc. |
| +0,16% | State Street Corp |
| +0,14% | HPM Partners LLC |
| +0,12% | Bank of America Corp |
| +0,12% | Northern Trust Corp |
| +0,11% | HighTower Advisors, LLC |
| +0,08% | UBS Group AG |
| +0,07% | Royal Bank of Canada |
| +0,02% | Founders Capital Management Inc |
| +0,02% | Tower Research Capital LLC |
| +0,00% | Morgan Stanley - Brokerage Accounts |
| +0,00% | SBI Securities Co Ltd |
| 0,00% | Barclays PLC |
| 0,00% | Cheviot Value Management, Inc. |
| 0,00% | Wells Fargo & Co |
| +19,12% | Weitere |
| +71,94% | Streubesitz |
Zahlen für Q2/24
- Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024
-Available cash projected to fund current operations into early 2026 and all active studies through to data